Palmitic acid reduces the methylation of the FOXO1 promoter to suppress the development of diffuse large B-cell lymphoma via modulating the miR-429/DNMT3A axis

Abstract

Diffuse large B-cell lymphoma (DLBCL) is characterized by significant treatment resistance. Palmitic acid (PA) has shown promising antitumor properties. This study aims to elucidate the molecular mechanisms by which PA influences DLBCL progression. We quantified the expression levels of microRNAs (miRNAs), Forkhead box protein O1 (FOXO1), and DNA methyltransferase 3A (DNMT3A) in both untreated and PA-treated DLBCL tumors and cell lines. Assessments were made of cell viability, apoptosis, and autophagy-related protein expression following PA administration. Interaction analyses among miR-429, DNMT3A, and FOXO1 were conducted using luciferase reporter assays and methylation-specific (MSP) Polymerase chain reaction (PCR). After transfecting the miR-429 inhibitor, negative control (NC) inhibitor, shRNA against DNMT3A (sh-DNMT3A), shRNA negative control (sh-NC), overexpression vector for DNMT3A (oe-DNMT3A), or overexpression negative control (oe-NC), we evaluated the effects of miR-429 and DNMT3A on cell viability, mortality, and autophagy-related protein expression in PA-treated DLBCL cell lines. The efficacy of PA was also tested in vivo using DLBCL tumor-bearing mouse models. MiR-429 and FOXO1 expression levels were downregulated, whereas DNMT3A was upregulated in DLBCL compared to the control group. PA treatment was associated with enhanced autophagy, mediated by the upregulation of miR-429 and downregulation of DNMT3A. The luciferase reporter assay and MSP confirmed that miR-429 directly inhibits DNMT3A, thereby reducing FOXO1 methylation. Subsequent experiments demonstrated that PA promotes autophagy and inhibits DLBCL progression by upregulating miR-429 and modulating the DNMT3A/FOXO1 axis. In vivo PA significantly reduced the growth of xenografted tumors through its regulatory impact on the miR-429/DNMT3A/FOXO1 axis. Palmitic acid may modulate autophagy and inhibit DLBCL progression by targeting the miR-429/DNMT3A/FOXO1 signaling pathway, suggesting a novel therapeutic target for DLBCL management.

Keywords

Palmitic acid / Diffuse large B-cell lymphoma / MiR-429 / DNMT3A / FOXO1 / Autophagy

References

[1] Sehn LH, Salles G. Diffuse large B-Cell lymphoma[J]. N Engl J Med, 2021, 384(9): 842-858.

[2] Cheson BD, Nowakowski G, Salles G. Diffuse large B-cell lymphoma: new targets and novel therapies[J]. Blood Cancer J, 2021, 11(4): 68.

[3] Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse Large B-Cell Lymphoma[J]. N Engl J Med, 2018, 378(15): 1396-1407.

[4] He MY, Kridel R. Treatment resistance in diffuse large B-cell lymphoma[J]. Leukemia, 2021, 35(8): 2151-2165.

[5] Urso CJ, Zhou H. Palmitic acid lipotoxicity in microglia cells is ameliorated by unsaturated fatty acids[J]. Int J Mol Sci, 2021, 22(16): 9093.

[6] Zhu S, Jiao W, Xu Y, et al. Palmitic acid inhibits prostate cancer cell proliferation and metastasis by suppressing the PI3K/Akt pathway[J]. Life Sci, 2021, 286: 120046.

[7] Binker-Cosen MJ, Richards D, Oliver B, et al. Palmitic acid increases invasiveness of pancreatic cancer cells AsPC-1 through TLR4/ROS/NF-κB/MMP-9 signaling pathway[J]. Biochem Biophys Res Commun, 2017, 484(1): 152-158.

[8] Maly IV, Hofmann WA. Effect of palmitic acid on exosome-mediated secretion and invasive motility in prostate cancer cells[J]. Molecules, 2020, 25(12): 2722.

[9] Tu QQ, Zheng RY, Li J, et al. Palmitic acid induces autophagy in hepatocytes via JNK2 activation[J]. Acta Pharmacol Sin, 2014, 35(4): 504-512.

[10] Yu DY, Zhao QL, Furuta M, et al. Molecular mechanisms of apoptosis induction by 2-dodecylcyclobutanone, a radiolytic product of palmitic acid, in human lymphoma U937 cells[J]. Apoptosis, 2012, 17(6): 636-645.

[11] Roy SG. Regulation of autophagy by miRNAs in human diseases[J]. Nucleus (Calcutta), 2021, 64(3): 317-329.

[12] Feng Y, Zhong M, Zeng S, et al. Exosome-derived miRNAs as predictive biomarkers for diffuse large B-cell lymphoma chemotherapy resistance[J]. Epigenomics, 2019, 11(1): 35-51.

[13] Zhang L, Liu Q, Mu Q, et al. MiR-429 suppresses proliferation and invasion of breast cancer via inhibiting the Wnt/β-catenin signaling pathway[J]. Thorac Cancer, 2020, 11(11): 3126-3138.

[14] Liu D, Song L, Dai Z, et al. MiR-429 suppresses neurotrophin-3 to alleviate perineural invasion of pancreatic cancer[J]. Biochem Biophys Res Commun, 2018, 505(4): 1077-1083.

[15] Liang Y, Yu ZJ, Liu M, et al. hsa-miR-429 targets CBX8 to promote cell apoptosis in diffuse large B-cell lymphoma[J]. Mol Med Rep, 2021, 24(6).

[16] Getaneh Z, Asrie F, Melku M. MicroRNA profiles in B-cell non-Hodgkin lymphoma[J]. Ejifcc, 2019, 30(2): 195-214.

[17] Li E, Zhang Y. DNA methylation in mammals[J]. Cold Spring Harb Perspect Biol, 2014, 6(5): a019133.

[18] Chambwe N, Kormaksson M, Geng H, et al. Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes[J]. Blood, 2014, 123(11): 1699-1708.

[19] Bakhshi TJ, Georgel PT. Genetic and epigenetic determinants of diffuse large B-cell lymphoma[J]. Blood Cancer J, 2020, 10(12): 123.

[20] Dhanak D, Jackson P. Development and classes of epigenetic drugs for cancer[J]. Biochem Biophys Res Commun, 2014, 455(1-2): 58-69.

[21] Zhao H, Zhang LE, Guo S, et al. Overexpression of DNA methyltransferase 1 as a negative independent prognostic factor in primary gastrointestinal diffuse large B-cell lymphoma treated with CHOP-like regimen and rituximab[J]. Oncol Lett, 2015, 9(5): 2307-2312.

[22] Mancini M, Grasso M, Muccillo L, et al. DNMT3A epigenetically regulates key microRNAs involved in epithelial-to-mesenchymal transition in prostate cancer[J]. Carcinogenesis, 2021, 42(12): 1449-1460.

[23] Hegde M, Joshi MB. Comprehensive analysis of regulation of DNA methyltransferase isoforms in human breast tumors[J]. J Cancer Res Clin Oncol, 2021, 147(4): 937-971.

[24] Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma[J]. Pathology, 2018, 50(1): 74-87.

[25] Duan Q, Li Y, Ou L, et al. Global research trends on the treatment of diffuse large B-Cell lymphoma: a bibliometric and visualized study[J]. J Cancer, 2022, 13(6): 1785-1795.

[26] Song Y, Zhou H, Zhang H, et al. Efficacy and safety of the biosimilar IBI301 plus standard CHOP (I-CHOP) in comparison with Rituximab plus CHOP (R-CHOP) in patients with previously untreated diffuse large B-Cell lymphoma (DLBCL): a randomized, double-blind, parallel-group, phase 3 trial[J]. Adv Ther, 2021, 38(4): 1889-1903.

[27] Hu J, Xu J, Yu M, et al. An integrated prognosis model of pharmacogenomic gene signature and clinical information for diffuse large B-cell lymphoma patients following CHOP-like chemotherapy[J]. J Transl Med, 2020, 18(1): 144.

[28] Li X, Huang H, Xu B, et al. Dose-dense Rituximab-CHOP versus Standard Rituximab-CHOP in newly diagnosed Chinese patients with diffuse large B-Cell lymphoma: a randomized, multicenter, open-label phase 3 trial[J]. Cancer Res Treat, 2019, 51(3): 919-932.

[29] Liu Y, Zeng L, Zhang S, et al. Identification of differentially expressed proteins in chemotherapy-sensitive and chemotherapy-resistant diffuse large B cell lymphoma by proteomic methods[J]. Med Oncol, 2013, 30(2): 528.

[30] Alkan HF, Altea-Manzano P, Fendt SM. Palmitic acid: enabling the tumor’s nerves[J]. Cell Metab, 2022, 34(1): 7-9.

[31] Beloribi-Djefaflia S, Vasseur S, Guillaumond F. Lipid metabolic reprogramming in cancer cells[J]. Oncogenesis, 2016, 5(1): e189.

[32] Fiorentino M, Zadra G, Palescandolo E, et al. Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of beta-catenin in prostate cancer[J]. Lab Invest, 2008, 88(12): 1340-1348.

[33] Nguyen MT, Min KH, Lee W. Palmitic acid-induced miR-429-3p impairs myoblast differentiation by downregulating CFL2[J]. Int J Mol Sci, 2021, 22(20): 10972.

[34] Thorsen SB, Obad S, Jensen NF, et al. The therapeutic potential of microRNAs in cancer[J]. Cancer J, 2012, 18(3): 275-284.

[35] Afonso-Grunz F, Müller S. Principles of miRNA-mRNA interactions: beyond sequence complementarity[J]. Cell Mol Life Sci, 2015, 72(16): 3127-3141.

[36] Cottrell KA, Szczesny P, Djuranovic S. Translation efficiency is a determinant of the magnitude of miRNA-mediated repression[J]. Sci Rep, 2017, 7(1): 14884.

[37] Jiang Y, Zhu H, Chen Z, et al. Hepatic IGF2/H19 epigenetic alteration induced glucose intolerance in gestational diabetes mellitus offspring via FoxO1 mediation[J]. Front Endocrinol (Lausanne), 2022, 13: 844707.

[38] Zhao Y, Yang J, Liao W, et al. Cytosolic FoxO1 is essential for the induction of autophagy and tumour suppressor activity[J]. Nat Cell Biol, 2010, 12(7): 665-675.

Funding

Study on the role and mechanism of Xiakucao extract in regulating autophagy therapy for diffuse large B-cell lymphoma through the PI3K/AKT signaling pathway(232102310451)

Study on the effect and mechanism of Xiakucao extract on diffuse large B-cell lymphoma(2022ZYBJ18)